Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 19/20 | 0.65 |
| ▸ | HCRTR2 | O43614 | 19/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSPO | P30536 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547533 | 0.92 | HCRTR1 (0.77) | HCRTR1HCRTR2 | |
| SCHEMBL954049 | 0.88 | CYP3A4 (0.61) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL951140 | 0.88 | CYP3A4 (0.62) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL933952 | 0.86 | CYP3A4 (0.62) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL933525 | 0.86 | CYP3A4 (0.62) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL934041 | 0.86 | CYP3A4 (0.67) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL935046 | 0.86 | CYP3A4 (0.67) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL934043 | 0.86 | CYP3A4 (0.67) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL4547536 | 0.84 | HCRTR1 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL6868061 | 0.83 | HCRTR1 (0.54) | HCRTR1HCRTR2TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | HCRTR1 15/4885HCRTR2 55/4885CYP3A4 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.